Chardan Capital Forecasts Strong Price Appreciation for Palvella Therapeutics (NASDAQ:PVLA) Stock

Palvella Therapeutics (NASDAQ:PVLA) had its price target boosted by stock analysts at Chardan Capital from $73.00 to $110.00 in a research report issued on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. Chardan Capital’s price objective suggests a potential upside of 41.33% from the company’s current price.

A number of other equities research analysts have also recently commented on the stock. Canaccord Genuity Group increased their target price on shares of Palvella Therapeutics from $66.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, October 9th. Oppenheimer started coverage on Palvella Therapeutics in a report on Tuesday, September 9th. They issued an “outperform” rating and a $85.00 target price for the company. Truist Financial lifted their target price on shares of Palvella Therapeutics from $56.00 to $80.00 and gave the stock a “buy” rating in a research note on Thursday, October 2nd. HC Wainwright raised their price objective on Palvella Therapeutics from $95.00 to $190.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, Raymond James Financial set a $54.00 price objective on shares of Palvella Therapeutics and gave the stock an “outperform” rating in a report on Tuesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $97.58.

Palvella Therapeutics Trading Down 1.0%

Shares of PVLA stock traded down $0.80 during trading hours on Friday, hitting $77.83. The company’s stock had a trading volume of 103,901 shares, compared to its average volume of 115,893. The company has a 50 day moving average of $65.65 and a 200 day moving average of $42.39. The stock has a market cap of $860.80 million, a PE ratio of -20.54 and a beta of -0.05. Palvella Therapeutics has a 12-month low of $11.17 and a 12-month high of $83.00.

Palvella Therapeutics (NASDAQ:PVLA) last released its quarterly earnings data on Thursday, August 14th. The company reported ($0.86) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.08). As a group, analysts anticipate that Palvella Therapeutics will post -3.69 earnings per share for the current fiscal year.

Institutional Trading of Palvella Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Archer Investment Corp acquired a new stake in Palvella Therapeutics in the third quarter valued at $28,000. JPMorgan Chase & Co. boosted its holdings in Palvella Therapeutics by 33.7% in the third quarter. JPMorgan Chase & Co. now owns 4,338 shares of the company’s stock valued at $272,000 after acquiring an additional 1,093 shares during the last quarter. Police & Firemen s Retirement System of New Jersey acquired a new position in Palvella Therapeutics during the second quarter valued at approximately $37,000. AlphaQuest LLC purchased a new position in Palvella Therapeutics in the third quarter valued at about $164,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Palvella Therapeutics in the 2nd quarter worth approximately $85,000. Institutional investors and hedge funds own 40.11% of the company’s stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.